{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:02:41Z","timestamp":1793678561133,"version":"4.5.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R34 MH100276"],"award-info":[{"award-number":["R34 MH100276"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Molecular Autism"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Phelan-McDermid syndrome (PMS) is caused by haploinsufficiency of the <jats:italic>SHANK3<\/jats:italic> gene and is characterized by global developmental delays and autism spectrum disorder (ASD). Based on several converging lines of preclinical and clinical evidence supporting the use of insulin-like growth factor-1 (IGF-1) in PMS, this study aims to follow-up a previous pilot study with IGF-1 to further evaluate this novel therapeutic for core symptoms of ASD in children with PMS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ten children aged 5\u20139 with PMS were enrolled. Participants were randomized to receive IGF-1 or placebo (saline) using a 12-week, double-blind, crossover design. Efficacy was assessed using the primary outcome of the Aberrant Behavior Checklist\u2014Social Withdrawal (ABC-SW) subscale as well as secondary outcome measures reflecting core symptoms of ASD. To increase power and sample size, we jointly analyzed the effect of IGF-1 reported here together with results from our previous controlled trail of IGF-1 in children with PMS (combined N\u2009=\u200919).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Results on the ABC-SW did not reach statistical significance, however significant improvements in sensory reactivity symptoms were observed. In our pooled analyses, IGF-1 treatment also led to significant improvements in repetitive behaviors and hyperactivity. There were no other statistically significant effects seen across other clinical outcome measures. IGF-1 was well tolerated and there were no serious adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Limitations<\/jats:title>\n                <jats:p>The small sample size and expectancy bias due to relying on parent reported outcome measures may contribute to limitations in interpreting results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IGF-1 is efficacious in improving sensory reactivity symptoms, repetitive behaviors, and hyperactivity\u00a0 in children with PMS.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> NCT01525901.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13229-022-00493-7","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:02:58Z","timestamp":1649419378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Clinical trial of insulin-like growth factor-1 in Phelan-McDermid syndrome"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8129-2671","authenticated-orcid":false,"given":"A.","family":"Kolevzon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-939X","authenticated-orcid":false,"given":"M. S.","family":"Breen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-8232","authenticated-orcid":false,"given":"P. M.","family":"Siper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6745-1197","authenticated-orcid":false,"given":"D.","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0979-1032","authenticated-orcid":false,"given":"Y.","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Weismann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7442-3677","authenticated-orcid":false,"given":"M. P.","family":"Trelles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9032-1224","authenticated-orcid":false,"given":"B.","family":"Lerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0915-3551","authenticated-orcid":false,"given":"R.","family":"Rapaport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-8313","authenticated-orcid":false,"given":"J. D.","family":"Buxbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"issue":"2","key":"493_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00441-006-0274-5","volume":"326","author":"TM Boeckers","year":"2006","unstructured":"Boeckers TM. The postsynaptic density. Cell Tissue Res. 2006;326(2):409\u201322.","journal-title":"Cell Tissue Res"},{"issue":"7","key":"493_CR2","doi-asserted-by":"publisher","first-page":"e1002173","DOI":"10.1371\/journal.pgen.1002173","volume":"7","author":"MC Bonaglia","year":"2011","unstructured":"Bonaglia MC, Giorda R, Beri S, De Agostini C, Novara F, Fichera M, et al. Molecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan\/McDermid syndrome. PLoS Genet. 2011;7(7):e1002173.","journal-title":"PLoS Genet"},{"issue":"10","key":"493_CR3","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/jmg.2005.038604","volume":"43","author":"MC Bonaglia","year":"2006","unstructured":"Bonaglia MC, Giorda R, Mani E, Aceti G, Anderlid BM, Baroncini A, et al. Identification of a recurrent breakpoint within the SHANK3 gene in the 22q13.3 deletion syndrome. J Med Genet. 2006;43(10):822\u20138.","journal-title":"J Med Genet"},{"issue":"1","key":"493_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2040-2392-4-17","volume":"4","author":"C Betancur","year":"2013","unstructured":"Betancur C, Buxbaum JD. SHANK3 haploinsufficiency: a \u201ccommon\u201d but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders. Mol Autism. 2013;4(1):17. https:\/\/doi.org\/10.1186\/2040-2392-4-17.","journal-title":"Mol Autism."},{"issue":"5","key":"493_CR5","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.neuron.2010.08.007","volume":"67","author":"T Nishijima","year":"2010","unstructured":"Nishijima T, Piriz J, Duflot S, Fernandez AM, Gaitan G, Gomez-Pinedo U, Verdugo JM, Leroy F, Soya H, Nu\u00f1ez A, Torres-Aleman I. Neuronal activity drives localized blood-brain-barrier transport of serum insulin-like growth factor-I into the CNS. Neuron. 2010;67(5):834\u201346.","journal-title":"Neuron"},{"issue":"22","key":"493_CR6","doi-asserted-by":"publisher","first-page":"8435","DOI":"10.1523\/JNEUROSCI.20-22-08435.2000","volume":"20","author":"JR O'Kusky","year":"2000","unstructured":"O\u2019Kusky JR, Ye P, D\u2019Ercole AJ. Insulin-like growth factor-I promotes neurogenesis and synaptogenesis in the hippocampal dentate gyrus during postnatal development. J Neurosci. 2000;20(22):8435\u201342.","journal-title":"J Neurosci"},{"issue":"1","key":"493_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2040-2392-4-9","volume":"4","author":"O Bozdagi","year":"2013","unstructured":"Bozdagi O, Tavassoli T, Buxbaum JD. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol Autism. 2013;4(1):9.","journal-title":"Mol Autism"},{"issue":"7475","key":"493_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nature12618","volume":"503","author":"A Shcheglovitov","year":"2013","unstructured":"Shcheglovitov A, Shcheglovitova O, Yazawa M, Portmann T, Shu R, Sebastiano V, Krawisz A, Froehlich W, Bernstein JA, Hallmayer JF, Dolmetsch RE. SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature. 2013;503(7475):267\u201371. https:\/\/doi.org\/10.1038\/nature12618 (Epub 2013 Oct 16).","journal-title":"Nature"},{"issue":"1","key":"493_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/2040-2392-5-54","volume":"5","author":"A Kolevzon","year":"2014","unstructured":"Kolevzon A, Bush L, Wang AT, Halpern D, Frank Y, Grodberg D, Rapaport R, Tavassoli T, Chaplin W, Soorya L, Buxbaum JD. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome. Mol Autism. 2014;5(1):54. https:\/\/doi.org\/10.1186\/2040-2392-5-54 (Erratum in: Mol Autism. 2015;6:31).","journal-title":"Mol Autism"},{"issue":"12","key":"493_CR10","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1073\/pnas.1311141111","volume":"111","author":"OS Khwaja","year":"2014","unstructured":"Khwaja OS, Ho E, Barnes KV, O\u2019Leary HM, Pereira LM, Finkelstein Y, Nelson CA III, Vogel-Farley V, DeGregorio G, Holm IA, Khatwa U, Kapur K, Alexander ME, Finnegan DM, Cantwell NG, Walco AC, Rappaport L, Gregas M, Fichorova RN, Shannon MW, Sur M, Kaufmann WE. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci USA. 2014;111(12):4596\u2013601.","journal-title":"Proc Natl Acad Sci USA"},{"key":"493_CR11","first-page":"5073078","volume":"2016","author":"G Pini","year":"2016","unstructured":"Pini G, Congiu L, Benincasa A, DiMarco P, Bigoni S, Dyer AH, Mortimer N, Della-Chiesa A, O\u2019Leary S, McNamara R, Mitchell KJ, Gill M, Tropea D. Illness severity, social and cognitive ability, and EEG Analysis of ten patients with Rett syndrome treated with Mecasermin (recombinant human IGF-1). Autism Res Treat. 2016;2016:5073078 (Epub 2016 Jan 26).","journal-title":"Autism Res Treat"},{"key":"493_CR12","doi-asserted-by":"crossref","unstructured":"Berry-Kravis E, Horrigan JP, Tartaglia N, Hagerman R, Kolevzon A, Erickson CA, Hatti S, Snape M, Yaroshinsky A, Stoms G; FXS-001 Investigators, Glass L, Jones NE. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of fragile X syndrome. Pediatr Neurol. 2020;110:30\u201341.","DOI":"10.1016\/j.pediatrneurol.2020.04.019"},{"key":"493_CR13","volume-title":"The autism diagnostic observation schedule, second edition (ADOS-2) manual (part 1): modules 1\u20134","author":"C Lord","year":"2012","unstructured":"Lord C, Rutter M, DiLavore PC, Risi S, Gotham K, Bishop D. The autism diagnostic observation schedule, second edition (ADOS-2) manual (part 1): modules 1\u20134. Western Psychological Services; 2012."},{"key":"493_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/BF02172145","volume":"24","author":"C Lord","year":"1994","unstructured":"Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659\u201385.","journal-title":"J Autism Dev Disord"},{"key":"493_CR15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). American Psychiatric Publishing; 2013."},{"issue":"5","key":"493_CR16","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic. 1985;89(5):485\u201391.","journal-title":"Am J Ment Defic."},{"issue":"3","key":"493_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/a:1005596502855","volume":"30","author":"JW Bodfish","year":"2000","unstructured":"Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000;30(3):237\u201343. https:\/\/doi.org\/10.1023\/a:1005596502855.","journal-title":"J Autism Dev Disord."},{"issue":"1","key":"493_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5014\/ajot.51.1.25","volume":"51","author":"W Dunn","year":"1997","unstructured":"Dunn W, Westman K. The sensory profile: the performance of a national sample of children without disabilities. Am J Occup Ther. 1997;51(1):25\u201334. https:\/\/doi.org\/10.5014\/ajot.51.1.25.","journal-title":"Am J Occup Ther."},{"key":"493_CR19","volume-title":"Clinical global impressions ECDEU assessment manual for psychopharmacology","author":"W Guy","year":"1976","unstructured":"Guy W. Clinical global impressions ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institute for Mental Health; 1976."},{"issue":"15","key":"493_CR20","first-page":"276","volume":"109","author":"S Wellek","year":"2012","unstructured":"Wellek S, Blettner M. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications. Deutsch \u00c4rztebl Int. 2012;109(15):276.","journal-title":"Deutsch \u00c4rztebl Int"},{"issue":"7","key":"493_CR21","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1007\/s10803-016-2754-0","volume":"46","author":"AM Mieses","year":"2016","unstructured":"Mieses AM, Tavassoli T, Li E, Soorya L, Lurie S, Wang AT, Siper PM, Kolevzon A. Brief report: sensory reactivity in children with Phelan-McDermid syndrome. J Autism Dev Disord. 2016;46(7):2508\u201313. https:\/\/doi.org\/10.1007\/s10803-016-2754-0.","journal-title":"J Autism Dev Disord"},{"issue":"7","key":"493_CR22","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/genes12070977","volume":"12","author":"T Tavassoli","year":"2021","unstructured":"Tavassoli T, Layton C, Levy T, Rowe M, George-Jones J, Zweifach J, Lurie S, Buxbaum JD, Kolevzon A, Siper PM. Sensory reactivity phenotype in Phelan-McDermid syndrome is distinct from idiopathic ASD. Genes (Basel). 2021;12(7):977. https:\/\/doi.org\/10.3390\/genes12070977.","journal-title":"Genes (Basel)"},{"issue":"1","key":"493_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13229-022-00485-7","volume":"13","author":"S Sethuram","year":"2022","unstructured":"Sethuram S, Levy T, Foss-Feig J, Halpern D, Sandin S, Siper PM, Walker H, Buxbaum JD, Rapaport R, Kolevzon A. A proof-of-concept study of growth hormone in children with Phelan-McDermid syndrome. Mol Autism. 2022;13(1):6. https:\/\/doi.org\/10.1186\/s13229-022-00485-7.","journal-title":"Mol Autism."},{"issue":"1","key":"493_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13052-021-01003-w","volume":"47","author":"RJ Xie","year":"2021","unstructured":"Xie RJ, Li TX, Sun C, Cheng C, Zhao J, Xu H, Liu Y. A case report of Phelan-McDermid syndrome: preliminary results of the treatment with growth hormone therapy. Ital J Pediatr. 2021;47(1):49. https:\/\/doi.org\/10.1186\/s13052-021-01003-w (Erratum in: Ital J Pediatr. 2021;47(1):89).","journal-title":"Ital J Pediatr"}],"container-title":["Molecular Autism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-022-00493-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13229-022-00493-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13229-022-00493-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:19:44Z","timestamp":1649420384000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularautism.biomedcentral.com\/articles\/10.1186\/s13229-022-00493-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["493"],"URL":"https:\/\/doi.org\/10.1186\/s13229-022-00493-7","relation":{},"ISSN":["2040-2392"],"issn-type":[{"value":"2040-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"12 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Mount Sinai Program for the Protection of Human Subjects and all caregivers signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AK receives research support from AMO Pharma and consults to Acadia, Alkermes, Ritrova, Jaguar, Neuren, GW Pharma, and Ovid Therapeutics. JDB has a shared patent with Mount Sinai for IGF-1 in Phelan-McDermid syndrome. No other authors have competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}